References
- Nii T, Kuzuya K, Kabata D, Matsui T, Murata A, Ohya T, et al. Crosstalk between tumor necrosis factor-alpha signaling and aryl hydrocarbon receptor signaling in nuclear factor-kappa B activation: a possible molecular mechanism underlying the reduced efficacy of TNF-inhibitors in rheumatoid arthritis by smoking. J Autoimmun 2019;98:95–102.
- Plant D, Barton A, Thomson W, Ke X, Eyre S, Hinks A, et al. Re-evaluation of three putative functional single nucleotide polymorphisms in rheumatoid arthritis. Ann Rheum Dis 2009;68:1373–5.
- Bek S, Bojesen AB, Nielsen JV, Sode J, Bank S, Vogel U, et al. Systemic review and meta-analysis: pharmacogenetics of anti-TNF treatment response in rheumatoid arthritis. Pharmacogenomics J 2017;17:403–11.
- Lopez-Rodriguez R, Perez-Pampin E, Marquez A, Blanco FJ, Joven B, Carreira P, et al. Validation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis. PLoS One 2018;13:e0196793.
- Liu YC, Penninger J, Karin M. Immunity by ubiquitylation: a reversible process of modification. Nat Rev Immunol 2005;5:941–52.
- Ma A, Malynn BA. A20: linking a complex regulator of ubiquitylation to immunity and human disease. Nat Rev Immunol 2012;12:774–85.
- Shimane K, Kochi Y, Horita T, Ikari K, Amano H, Hirakata M, etal. The association of nonsynonymous single-nucleotide polymorphism in TNFAIP3 with systemic lupus erythematosus and rheumatoid arthritis in the Japanese population. Arthritis Rheum 2010;62:574–9.
- Sanger F, Nicken S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 1977;74:5463–7.
- Fransen J, van Riel PLCM. The disease activity score and the EULAR response criteria. Clin Exp Rheumatol 2005;23:S93–9.